VEXIM Obtains CE Approval to Market MasterflowTM Injection System in Europe

Regulatory News:

VEXIM (Paris:ALVXM) (FR0011072602 – ALVXM / PEA-PME eligible), a medical device company specializing in the minimally invasive treatment of vertebral fractures, announced today the grant of the European CE approval of Masterflow ^TM1, a fully integrated system for mixing and injecting orthopedic cement for vertebral augmentations.

The Masterflow^TM Injection System for Vertebral Augmentation now affords a more intuitive process for accessing the vertebral body for cement delivery and is unique in its simplicity, accuracy and control of the injection of high-viscosity cement to treat vertebral compression fractures.

Masterflow^TM was introduced in the U.S. market at the beginning of the year.

This patented system optimizes each stage of the injection process maximizing patients’ and surgeons’ safety, including:

• Complete control of the delivery of high viscosity cement with immediate halting of the flow
• Complete optimization of the procedure, which enhances clinical performance

Masterflow^TM complements the Company’s SpineJack® technology by expanding its presence in the field of vertebroplasty, which currently represents approximately half of the minimally invasive procedures to treat vertebral compression.

Vincent Gardès, CEO of VEXIM, concludes: «This marks major progress toward our goal of continuously applying new technology to the field of vertebroplasty. Thanks to this new solution, we pledge to become even more innovative every year in order to continually strengthen our competitive advantage. With the Masterflow^TM Injection system now available in the U.S. and Europe, we are highly confident we can meet our growth goals in 2015. »

***

About Vexim, the innovative back microsurgery specialist
Based in Balma, near Toulouse (France), Vexim is a medical device company created in February 2006. The Company has specialized in the creation and marketing of minimally-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of it longstanding shareholder, Truffle Capital² and from OSEO public subsidies, Vexim has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 60 members on its staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland, the United Kingdom and United States, as well as distributors in Turkey, Argentina, Taiwan, Belgium, Estonia, Poland, Portugal, South Africa, Saudi Arabia, Colombia, Panama, Venezuela, Chile, Peru and Ecuador and in the following countries where the product is currently being registered: Mexico, Brazil. Vexim has been listed on NYSE Alternext Paris since May 2012. For further information, please visit www.vexim.com

SpineJack®³, a revolutionary implant for treating Vertebral Compression Fractures
The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by minimally-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies.
SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection through to 2029.

• Name: VEXIM
• ISIN code: FR0011072602
• Ticker: ALVXM

¹ This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.
² Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.
³ This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.